Abstract: A supportive clothing article for a wearable cardioverter defibrillator (WCD), including a belt, the belt including a first end with a first portion of a fastener and a second end with a second portion of the fastener, wherein the belt is structured to fasten around the torso of patient below the chest area of the patient, the belt including a first conductive mesh portion adjacent the first end of the belt or the second end of the belt, two straps, a back portion extending from the belt at an intermediary position on the belt to each of the two straps, the back portion including a conductive mesh, a first support receptacle attached to and extending from the belt and attachable to one of the two straps, and a second support receptacle attached to and extending from the belt and attachable to the other of the two straps.

Abstract: A wearable cardioverter defibrillator (WCD) system comprises a plurality of patient parameter electrodes and a plurality of defibrillator electrodes to contact a patient's skin when the WCD is delivering therapy to the patient, a processor to receive one or more patient parameters from the one or more patient parameter electrodes, an energy storage device to store a charge to provide electrical therapy to the patient via the plurality of defibrillator electrodes, and a non-invasive blood pressure (NIBP) monitor to obtain a blood pressure measurement of the patient and to provide the blood pressure measurement to the processor. The processor is to determine whether to provide electrical therapy to the patient based on the one or more patient parameters during an episode, and to obtain the blood pressure measurement from the NIBP monitor during the episode.

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I) or (Ia)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

Abstract: Some embodiments of the invention include methods of using a compound (e.g., Formula (I)) for the reduction of carbon dioxide to formate by contacting the carbon dioxide with a composition comprising a compound. In certain embodiments, the source of the carbon dioxide is air or is flue gas. Additional embodiments of the invention are also discussed herein.

Abstract: In some embodiments, this application relates to inventive compounds (e.g., Formula (I), Formula (II), thiosemicarbazones and/or thiosemicarbazones and their metal (e.g., zinc, cobalt, nickel, or copper) complexes, and extended structures thereof), methods for preparation of the inventive compounds, compositions comprising the inventive compounds (e.g., anode, cathodes, catalysts (e.g., electrocatalysts), glassy carbon electrodes, carbon paste electrodes, covalently modified carbon (e.g., modified graphene)), electrochemical cells comprising compositions that comprise one or more inventive compounds, fuel cells comprising compositions that comprise one or more inventive compounds, uses of one or more inventive compounds to produce H2 (e.g., via an electrochemical cell), and uses of one or more inventive compounds to create energy from H2 (e.g., via a fuel cell). Additional embodiments of the invention are also discussed herein.

Abstract: Some embodiments of the invention include methods of using a compound (e.g., Formula (I)) for the reduction of carbon dioxide to formate by contacting the carbon dioxide with a composition comprising a compound. In certain embodiments, the source of the carbon dioxide is air or is flue gas. Additional embodiments of the invention are also discussed herein.

Abstract: Some embodiments of the invention include methods of using a compound (e.g., Formula (I)) for the reduction of carbon dioxide to formate by contacting the carbon dioxide with a composition comprising a compound. In certain embodiments, the source of the carbon dioxide is air or is flue gas. Additional embodiments of the invention are also discussed herein.

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I) or (Ia)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

Abstract: In some embodiments, this application relates to inventive compounds (e.g., Formula (I), Formula (II), thiosemicarbazones and/or thiosemicarbazones and their metal (e.g., zinc, cobalt, nickel, or copper) complexes, and extended structures thereof), methods for preparation of the inventive compounds, compositions comprising the inventive compounds (e.g., anode, cathodes, catalysts (e.g., electrocatalysts), glassy carbon electrodes, carbon paste electrodes, covalently modified carbon (e.g., modified graphene)), electrochemical cells comprising compositions that comprise one or more inventive compounds, fuel cells comprising compositions that comprise one or more inventive compounds, uses of one or more inventive compounds to produce H2 (e.g., via an electrochemical cell), and uses of one or more inventive compounds to create energy from H2 (e.g., via a fuel cell). Additional embodiments of the invention are also discussed herein.

Abstract: Methods, materials and apparatus for production of hydrogen peroxide are disclosed. In one preferred embodiment, high surface area circulating elements derivatized with a quinone catalyst are reduced in an electrolytic cell where the cathode may also be derivatized with a quinone catalyst and a solution quinone at low concentration is used as a mediator. Once reduced, the circulating elements are separated and used to form hydrogen peroxide from molecular oxygen in an aqueous, electrolyte-free, environment. The circulating elements can be cycled repeatedly. Particular, novel naphthoquinone compounds are also disclosed.

Abstract: An apparatus for the production of hydrogen peroxide is disclosed. In one preferred embodiment, high surface area circulating elements derivatized with a quinone catalyst are reduced in an electrolytic cell where the cathode may also be derivatized with a quinone catalyst and a solution quinone at low concentration is used as a mediator. Once reduced, the circulating elements are separated and used to form hydrogen peroxide from molecular oxygen in an aqueous, electrolyte-free, environment. The circulating elements can be cycled repeatedly. Particular, novel naphthoquinone compounds are also disclosed.

Abstract: Methods, materials and apparatus for production of hydrogen peroxide are disclosed. In one preferred embodiment, high surface area circulating elements derivatized with a quinone catalyst are reduced in an electrolytic cell where the cathode may also be derivatized with a quinone catalyst and a solution quinone at low concentration is used as a mediator. Once reduced, the circulating elements are separated and used to form hydrogen peroxide from molecular oxygen in an aqueous, electrolyte-free, environment. The circulating elements can be cycled repeatedly. Particular, novel naphthoquinone compounds are also disclosed.